Table 1

Baseline characteristics of patients included in this study

Parameter

Responders

Non-responders

P value

(n = 42)

(n = 10)


Age in years, mean ± SE

62.7 ± 1.9

60.8 ± 3.1

NSa

Female gender, percentage

81.0

60.0

NSb

Disease duration in years, mean ± SE

11.7 ± 1.3

16.2 ± 3.9

NSa

ESRc, mean ± SE

39.2 ± 3.8

43.3 ± 11.8

NSa

DAS28-ESR, mean ± SE

5.9 ± 0.2

4.9 ± 0.3

0.016a

Lymphocytesd, mean ± SE

2,138 ± 174

3,083 ± 23

0.0279a

RF-positive, percentage

90.8

100.0

NSb

ACPA-positive, percentage

76.9

80.0

NSb

Double-seropositive, percentage

71.8

80.0

NSb

Double-seronegative, percentage

7.7

0.0

NSb

Concomitant MTX usage, percentage

40.4

41.7

NSb

Previous sDMARD, mean ± SE

2.6 ± 0.1

2.0 ± 0.3

NSa

Previous TNF inhibitors, mean ± SE

1.1 ± 0.1

1.4 ± 0.4

NSa

No previous biologics, percentage

24.3

11.1

NSb

One previous biologic, percentage

43.2

55.6

NSb

Two previous biologics, percentage

27.1

11.1

NSb

Three previous biologics, percentage

5.4

22.2

NSb

Systemic steroids, percentage

40.0

31.0

NSb


aP values were calculated by using Mann-Whitney test; bP values were calculated by using the chi-squared test; cmm per 1 hour; dG per liter (normal range is 1.0 to 4.8). ACPA, anti-citrullinated peptide antibody; DAS28, disease activity score using 28 joint counts; ESR, erythrocyte sedimentation rate; MTX, methotrexate; NS, not significant; RF, rheumatoid factor; sDMARD, synthetic disease-modifying anti-rheumatic drug; SE, standard error; TNF, tumor necrosis factor.

Brezinschek et al. Arthritis Research & Therapy 2012 14:R161   doi:10.1186/ar3901

Open Data